US stock yield curve analysis and recession indicator monitoring to understand broader economic health. Our macro research helps you anticipate market conditions that could impact your investment strategy.
This analysis covers the April 24, 2026 announcement that Bristol Myers Squibb (NYSE: BMY) and co-marketing partner Pfizer (NYSE: PFE) will list their top-selling anticoagulant Eliquis on the Mark Cuban Cost Plus Drug Company (MCCPDC) platform starting the following week, priced at $345 for a 30-day
Bristol Myers Squibb (BMY) - Partners With Pfizer to List Blockbuster Anticoagulant Eliquis on Mark Cuban Cost Plus Platform at $345 Monthly - Special Situation
BMY - Stock Analysis
4184 Comments
789 Likes
1
Lamoine
Power User
2 hours ago
Short-term swings are creating trading opportunities, though careful risk management is essential.
👍 208
Reply
2
Macie
Active Reader
5 hours ago
Too late to act… sigh.
👍 216
Reply
3
Bryttnii
Consistent User
1 day ago
This would’ve helped me avoid second guessing.
👍 82
Reply
4
Naiara
Trusted Reader
1 day ago
Who else is here because of this?
👍 77
Reply
5
Rickey
Influential Reader
2 days ago
This feels like instructions I forgot.
👍 182
Reply
© 2026 Market Analysis. All data is for informational purposes only.